Abstract
With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Cardiovascular & Hematological Disorders-Drug Targets
Title: Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Volume: 8 Issue: 2
Author(s): Lisa S. Rosenbaum and James L. Januzzi
Affiliation:
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Abstract: With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Export Options
About this article
Cite this article as:
Rosenbaum S. Lisa and Januzzi L. James, Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533711
DOI https://dx.doi.org/10.2174/187152908784533711 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Editorial from Guest Editor [Hot Topic Perinatal Stem Cells Revisited: Directions and Indications at the Crossroads Between Tissue Regeneration and Repair]
Current Stem Cell Research & Therapy The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Analytical Methods for the Determination of Anti-diuretic Peptides in Biological Samples: Challenges and Perspectives
Current Analytical Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Heart Disease Prediction System Using Decision Tree and Naive Bayes Algorithm
Current Medical Imaging The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Comparison Between 3D Echocardiography and Cardiac Magnetic Resonance Imaging (CMRI) in the Measurement of Left Ventricular Volumes and Ejection Fraction
Current Medical Imaging Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Measurement of Extravascular Lung Water in Critically Ill Patients
Current Respiratory Medicine Reviews Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design